Celcuity Inc. CELC
70.37 USD +3.58 (+5.36%)
At closeNov 9, 2026, 4:00 PM EST
70.37 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
66.40 Day range 72.24
53.54 52-week range 151.02
- YTD
- -29.45%
- 1 year
- -5.57%
News
benzinga.com Celcuity's Supplemental New Drug Application For REVTORPYK Accepted for FDA Review To Treat Hormone Receptor Positive Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today…
benzinga.com Block To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Monday Analysts raised targets for Magnite, Airbnb and Choice Hotels; cut targets for Unusual Machines, DraftKings, PDD and TeraWulf. DKNG and PDD downgraded.
benzinga.com HC Wainwright & Co. Maintains Buy on Celcuity, Lowers Price Target to $150 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $155 to $150.
benzinga.com Guggenheim Maintains Buy on Celcuity, Lowers Price Target to $169 Guggenheim analyst Michael Schmidt maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $171 to $169.
marketbeat.com What Celcuity (CELC) Said on Its Q3 Earnings Call Celcuity NASDAQ: CELC reported a wider third-quarter loss as it prepared to commercialize its breast cancer treatment REVTORPYK, while executives said early orders and insurance coverage pointed to…
benzinga.com Celcuity Q3 2026 Earnings Call Transcript Celcuity (NASDAQ:CELC) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com Celcuity Q3 Adj. EPS $(1.21) Beats $(1.43) Estimate, Sales $0.00 Miss $1.563M Estimate Celcuity (NASDAQ:CELC) reported quarterly losses of $(1.21) per share which beat the analyst consensus estimate of $(1.43) by 15.38 percent. This is a 55.13 percent decrease over losses of $(0.78)…
globenewswire.com Celcuity To Participate in Upcoming Investor Conferences MINNEAPOLIS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid…
benzinga.com Cantor Fitzgerald Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $140 Cantor Fitzgerald analyst Li Watsek initiates coverage on Celcuity (NASDAQ:CELC) with a Overweight rating and announces Price Target of $140.